News
Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...
How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.
6h
Zacks Investment Research on MSNWill CVS Health's Formulary Move Boost Its Weight Management Program? (Revised)For CVS Health CVS, the key to building customer trust is to enhance access to life-changing medications and also make them affordable. Beginning July 1, the company’s Pharmacy Benefit Manager (“PBM”) ...
7h
Zacks Investment Research on MSNHims & Hers vs. LifeMD: Which Telehealth Stock Has More Upside?Virtual healthcare services, or telehealth, are rapidly becoming a standard of care in the expanding digital healthcare space ...
Kanzen Meal is positioned as a nutrient-dense option that can meet the needs of individuals taking GLP-1 weight loss ...
RBC Capital Markets analysts believe Eli Lilly’s upcoming TRAILBLAZER-3 trial data on Kisunla could unlock a vast, largely untapped segment of the Alzheimer’s treatment market and pave the way for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results